Boston Scientific reins in Lotus Edge heart valve launch; shares dive more than 7%

Boston Scientific to delay U.S., European launch of Lotus heart valve system.

Boston Scientific, which earlier this year recalled its Lotus range of heart devices, said it was delaying the commercial release in the U.S. and Europe of its Lotus Edge aortic valve system. The news sent shares of the company tumbling 7.44% in trading Tuesday.

After last February’s voluntary recall of the Lotus and Lotus Edge devices following reports of problems with the locking mechanism, Boston Scientific revamped its design and manufacturing processes with the intent of re-introducing the product in the European market in early 2018 and applying for a PMA module with the FDA in January, the company said.

The company’s technology is used in TAVR, a minimally invasive procedure to replace a narrowed aortic valve that fails to open properly. Edwards Lifesciences is seen as a leader in the TAVR market, which analysts have pegged at surpassing the $5 billion mark by 2021.

Your Daily Newsletter — Free

Enjoying this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. To read on the go, sign up today to get biotech news and updates delivered right to your inbox!

An updated timeline for the Lotus Edge valve is expected to be addressed during the company’s fourth-quarter earnings call scheduled for Feb. 1, 2018.

"We continue to see value in the unique benefits of the Lotus Valve platform in treating patients with aortic stenosis," Mike Mahoney, chairman and CEO, said in a statement. “While we are disappointed in this delay to our timelines, we are working to carefully analyze and implement necessary modifications to pass our rigorous internal quality standards."

The company said it is working with U.S. and European regulators and providing updates about the delays. Additionally, it said the delay won’t have a material financial impact on either fourth-quarter or full-year 2017 guidance.